Insempra completes $20 million financing to advance the development of next-generation bio-based ingredients
"New technology platforms such as Insempra’s have the potential to dramatically change the manufacturing processes of multiple multibillion-dollar industries..."
Insempra announces the successful completion of a $20 million Series A financing round. Following an initial $15m seed round conducted in 2021, this financing round will enable Insempra, to continue building a technology platform that delivers high-performance, intrinsically sustainable ingredients for a wide range of industries, while supporting the company in the scale up of its technology scouting, development, and manufacturing capabilities.
Existing investors EQT Ventures,BlueYard Capital, Possible Ventures, Taavet Sten and Acequia Capital participated in the round. New investors are the corporate venture of international FMCG giant Henkel, Henkel dx Ventures, Bayern Kapital and Alante Capital.
Inspired to create a better future in collaboration with nature, Insempra takes a market-first approach to developing its science, creating ingredients that customers need. By harnessing new technologies to advance biological manufacturing processes, the company creates naturally superior products to drive the regenerative revolution. Insempra designs and builds these ingredients with atomic precision so that they can be rapidly produced and manufactured at scale, offering better solutions to agriculturally and petrochemically sourced oils and materials.
Driven by market need and collaborations with world-wide renowned consumer brands, Insempra is growing lipids for cosmetic and food applications. It is also developing technology that offers a bio-based alternative to everyday materials such as polymers and textiles and progressing its biological solutions to create new natural molecules for use in functional ingredients, such as antioxidants and preservatives and flavours and fragrances.
Jens Klein, founder, and CEO of Insempra, commented: “We are grateful for the support of this group of investors who have recognized the potential of Insempra’s market-first approach and innovative technology platforms. Working in collaboration with nature, we will continue to expand our capacity to develop intrinsically sustainable materials that are superior in quality and will reduce our dependency on chemical industrialization processes.”
Ted Persson, Partner at EQT Ventures, added: “Insempra has both the team and the technology to drive a revolution in industrial manufacturing and gain rapid market traction for its products. New technology platforms such as Insempra’s have the potential to dramatically change the manufacturing processes of multiple multibillion-dollar industries, developing customized ingredients to fit market needs.”
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
